Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvydas Mikulskis

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Immunological Methods|December 7, 2010
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug developmentAlvydas Mikulskis, Dave Yeung, Meena Subramanyam, et al.
Bioanalysis|September 14, 2017
Development of a plug and play ImmunoPCR technique for the analysis of biomoleculesSreeja Gopal, Shobha Purushothama, Alvydas Mikulskis, et al.
Journal of Immunological Methods|April 2, 2013
Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assaysAlvydas Mikulskis, Dave Yeung, Weiping Chen, et al.
Clinical Pharmacology : Advances and Applications|March 2, 2016
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosisJonathan Q Tran, Ahmed A Othman, Alvydas Mikulskis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2017
Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studiesSreeja Gopal, Alvydas Mikulskis, Ralf Gold, et al.
JAMA Neurology|November 9, 2017
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic AssessmentShorena Janelidze, Josef Pannee, Alvydas Mikulskis, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's diseaseJames Ferrero, Leslie Williams, Heather Stella, et al.
Neurobiology of Aging|November 25, 2018
Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activityBrian B Avants, R Matthew Hutchison, Alvydas Mikulskis, et al.
The AAPS Journal|October 22, 2014
Emerging technologies to increase ligand binding assay sensitivitySaloumeh K Fischer, Alison Joyce, Mark Spengler, et al.
Proteomics|July 23, 2003
High-content proteomics: fluorescence multiplexing using an integrated, high-sensitivity, multiwavelength charge-coupled device imaging systemMary F Lopez, Alvydas Mikulskis, Eva Golenko, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Immunological Methods|December 7, 2010
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug developmentAlvydas Mikulskis, Dave Yeung, Meena Subramanyam, et al.
Bioanalysis|September 14, 2017
Development of a plug and play ImmunoPCR technique for the analysis of biomoleculesSreeja Gopal, Shobha Purushothama, Alvydas Mikulskis, et al.
Journal of Immunological Methods|April 2, 2013
Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assaysAlvydas Mikulskis, Dave Yeung, Weiping Chen, et al.
Clinical Pharmacology : Advances and Applications|March 2, 2016
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosisJonathan Q Tran, Ahmed A Othman, Alvydas Mikulskis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2017
Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studiesSreeja Gopal, Alvydas Mikulskis, Ralf Gold, et al.
JAMA Neurology|November 9, 2017
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic AssessmentShorena Janelidze, Josef Pannee, Alvydas Mikulskis, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's diseaseJames Ferrero, Leslie Williams, Heather Stella, et al.
Neurobiology of Aging|November 25, 2018
Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activityBrian B Avants, R Matthew Hutchison, Alvydas Mikulskis, et al.
The AAPS Journal|October 22, 2014
Emerging technologies to increase ligand binding assay sensitivitySaloumeh K Fischer, Alison Joyce, Mark Spengler, et al.
Proteomics|July 23, 2003
High-content proteomics: fluorescence multiplexing using an integrated, high-sensitivity, multiwavelength charge-coupled device imaging systemMary F Lopez, Alvydas Mikulskis, Eva Golenko, et al.
Pageof 3